Nursing and Health Professions
Patient
100%
Carcinoembryonic Antigen
56%
Cytokeratin 19 Fragment
50%
Inpatient
37%
Epidermal Growth Factor Receptor
31%
Erlotinib
25%
Non Small Cell Lung Cancer
25%
Progression Free Survival
18%
Electrocorticography
18%
Overall Survival
12%
Predictive Value
12%
Adenocarcinoma
12%
Enalapril Maleate
12%
Squamous Cell Carcinoma
12%
Blood Level
6%
Prognosis
6%
Survival
6%
Marker
6%
Cytokeratin 19
6%
Medicine and Dentistry
Carcinoembryonic Antigen
56%
Cytokeratin 19 Fragment
50%
Epidermal Growth Factor Receptor
31%
Non Small Cell Lung Cancer
25%
Erlotinib
25%
Electrocorticography
18%
Progression Free Survival
18%
Adenocarcinoma
12%
Overall Survival
12%
Therapeutic Procedure
12%
Female
12%
Enalapril Maleate
12%
Serum
6%
Smoking
6%
Keratin 19
6%
Survival
6%
Marker
6%
Pharmacology, Toxicology and Pharmaceutical Science
Carcinoembryonic Antigen
56%
Cytokeratin 19 Fragment
50%
Epidermal Growth Factor Receptor
31%
Non Small Cell Lung Cancer
25%
Erlotinib
25%
Progression Free Survival
18%
Squamous Cell Carcinoma
12%
Overall Survival
12%
Adenocarcinoma
12%
Enalapril Maleate
12%
Prognosis
6%
Cytokeratin 19
6%
Survival
6%
Biochemistry, Genetics and Molecular Biology
Mutation
31%
Epidermal Growth Factor Receptor
31%
Carcinoembryonic Antigen
25%
Erlotinib
25%
Progression Free Survival
18%
Overall Survival
12%
Blood Level
6%
Smoking
6%
Keratin 19
6%
Survival
6%